Homeopathy. 2009 Jul; 98(3): 137-41Mousavi F, Mojaver YN, Asadzadeh M, Mirzazadeh MOBJECTIVE: The objectives of this study were to clinically determine the efficacy of individualised homeopathy in the treatment of minor recurrent aphthous ulceration (MiRAU). DESIGN & INTERVENTION: A randomized, single blind, placebo-controlled clinical trial of individualised homeopathy. One hundred patients with minor aphthous ulcer were treated with individualised homeopathic medicines or placebo and followed up for 6 days. Patients received two doses of individualised homeopathic medicines in the 6C potency as oral liquid at baseline and 12 h later. Pain intensity and ulcer size were recorded at baseline during and at the end of the trial (mornings of days 4 and 6). RESULT: All 100 patients completed treatment. Between group differences for pain intensity and ulcer size were statistically significant at day 4 and at day 6 (P

J Cell Mol Med. 2009 Jul 31; Xu X, Dai YIt was nearly one hundred years since heparin was discovered, but the role of this widely used anticoagulant is still remarkably thought-provoking now. During pathological processes such as atherosclerosis, inflammation, cancer and infection, phenomena of cell adhesion are ubiquitous and complicated. Heparin exerts anti-adhesion activity appearing as a common mechanism of its potential polypharmacology in those diseases. Furthermore, heparin can bind a variety of signaling molecules such growth factors, cell surface proteins of pathogens and most notably, cell adhesion molecules. These signaling molecules are involved in cell communication, acting as ligands, receptors, and second messengers. Considering that heparan sulfate glycosaminoglycan is increasingly recognized as a key mediator in many cellular processes, the structural similarity with heparan sulfate suggests that heparin is a multifunctional intervenor in cell communication.